- Home
- AKTX vs FGEN Comparison
AKTX vs FGEN Comparison
Compare AKTX & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKTX
- FGEN
- Stock Information
- Founded
- AKTX N/A
- FGEN 1993
- Country
- AKTX United States
- FGEN United States
- Employees
- AKTX N/A
- FGEN N/A
- Industry
- AKTX Biotechnology: Pharmaceutical Preparations
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- AKTX Health Care
- FGEN Health Care
- Exchange
- AKTX Nasdaq
- FGEN Nasdaq
- Market Cap
- AKTX 35.7M
- FGEN 38.4M
- IPO Year
- AKTX N/A
- FGEN 2014
- Fundamental
- Price
- AKTX $0.84
- FGEN $11.34
- Analyst Decision
- AKTX Strong Buy
- FGEN Strong Buy
- Analyst Count
- AKTX 1
- FGEN 2
- Target Price
- AKTX $5.00
- FGEN $146.50
- AVG Volume (30 Days)
- AKTX 85.8K
- FGEN 74.0K
- Earning Date
- AKTX 08-13-2025
- FGEN 08-11-2025
- Dividend Yield
- AKTX N/A
- FGEN N/A
- EPS Growth
- AKTX N/A
- FGEN N/A
- EPS
- AKTX N/A
- FGEN N/A
- Revenue
- AKTX N/A
- FGEN $7,346,000.00
- Revenue This Year
- AKTX N/A
- FGEN N/A
- Revenue Next Year
- AKTX N/A
- FGEN N/A
- P/E Ratio
- AKTX N/A
- FGEN N/A
- Revenue Growth
- AKTX N/A
- FGEN N/A
- 52 Week Low
- AKTX $0.57
- FGEN $4.50
- 52 Week High
- AKTX $3.85
- FGEN $21.94
- Technical
- Relative Strength Index (RSI)
- AKTX 44.86
- FGEN 59.41
- Support Level
- AKTX $0.57
- FGEN $10.65
- Resistance Level
- AKTX $1.01
- FGEN $12.60
- Average True Range (ATR)
- AKTX 0.07
- FGEN 0.86
- MACD
- AKTX -0.00
- FGEN -0.02
- Stochastic Oscillator
- AKTX 63.51
- FGEN 49.60
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.